PA
CLVS

Pinnacle Associates’s Clovis Oncology, Inc. CLVS Stock Holding History

Pinnacle Associates’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-620,203
Closed -$738K – 779
2022
Q3 		$738K Sell
620,203
-82,501
-12% -$129K 0.02% 444
2022
Q2 		$1.26M Sell
702,704
-3,512
-0.5% -$5.18K 0.03% 356
2022
Q1 		$1.43M Sell
706,216
-120
-0% -$236 0.03% 388
2021
Q4 		$1.91M Buy
706,336
+45,145
+7% +$167K 0.03% 358
2021
Q3 		$2.95M Sell
661,191
-24,790
-4% -$119K 0.05% 282
2021
Q2 		$3.98M Buy
685,981
+11,238
+2% +$65.8K 0.07% 243
2021
Q1 		$4.74M Sell
674,743
-29,227
-4% -$196K 0.09% 215
2020
Q4 		$3.38M Sell
703,970
-90,891
-11% -$460K 0.07% 240
2020
Q3 		$4.63M Sell
794,861
-33,700
-4% -$202K 0.11% 192
2020
Q2 		$5.59M Sell
828,561
-12,798
-2% -$96.9K 0.14% 163
2020
Q1 		$5.35M Buy
841,359
+212,999
+34% +$1.71M 0.16% 149
2019
Q4 		$6.55M Buy
+628,360
New +$4.57M 0.14% 166

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $1.21B AUM 20.39% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $160M AUM 21.24% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $808M AUM 51.1% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Pinnacle Associates's CLVS Position: Q4 2022 in Review

Pinnacle Associates sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 620,203 shares — an estimated $738K sold.

Pinnacle Associates first reported a position in CLVS in Q4 2019 and held it in 12 quarters. The position peaked at $6.55M in Q4 2019. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Pinnacle Associates reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • Pinnacle Associates sold 620,203 Clovis Oncology, Inc. shares in Q4 2022, an estimated $738K.
  • Pinnacle Associates first reported a position in Clovis Oncology, Inc. in Q4 2019 and held it in 12 quarters.
  • Pinnacle Associates's Clovis Oncology, Inc. position peaked at $6.55M in Q4 2019.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Pinnacle Associates's 13F filing for Q4 2022, filed 25 Jan 2023.